Is AMGN a Buy or a Sell? The Bull and Bear Case (2026)
Last updated July 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Amgen (AMGN) rests on Rare disease and Horizon assets: The Horizon Therapeutics acquisition added higher-growth rare-disease drugs such as Tepezza and Krystexxa, diversifying Amgen away from older, slower-growing franchises and giving it newer products with patent runway and pricing power in specialty markets. The bear case rests on amgen faces patent cliffs as older blockbusters lose exclusivity, exposing them to biosimilar competition and pricing pressure. Analysts covering it publish targets from $215.00 to $427.00 against a $392.26 price, so even the professionals disagree by 59% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Amgen (AMGN) is one of the world's largest biotechnology companies, developing, manufacturing, and selling human therapeutics primarily for serious illnesses. Its portfolio spans inflammation, oncology, cardiovascular disease, bone health, and rare diseases, with well-known products that have included Enbrel, Prolia and Xgeva, Repatha, Otezla, and a growing pipeline. Amgen pioneered large-scale recombinant-protein and antibody manufacturing and is a leader in biosimilars as older biologics lose patent protection. The 2023 acquisition of Horizon Therapeutics added rare-disease drugs such as Tepezza and Krystexxa. Amgen is also developing obesity and metabolic candidates, including investigational drugs in the GLP-1 class of weight-loss therapies. Headquartered in Thousand Oaks, California, and founded in 1980, Amgen is a member of the Dow Jones Industrial Average and returns substantial cash to shareholders through a growing dividend and buybacks.
The bull case: what would have to be true for $427.00
The most optimistic published target on AMGN is $427.00, +8.9% from the $392.26 price as of July 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Rare disease and Horizon assets.
The Horizon Therapeutics acquisition added higher-growth rare-disease drugs such as Tepezza and Krystexxa, diversifying Amgen away from older, slower-growing franchises and giving it newer products with patent runway and pricing power in specialty markets.
2. Obesity and metabolic pipeline.
Amgen is developing candidates in the obesity and metabolic space, including investigational GLP-1-class and related therapies. Success in this large and fast-growing market could provide a significant new growth driver, though the candidates must still clear late-stage trials and regulatory review.
3. Biosimilars and cash generation.
As blockbuster biologics lose exclusivity industrywide, Amgen is both defending its own products and selling biosimilars of competitors' drugs. Combined with strong free cash flow, this supports a growing dividend and buybacks, giving the stock an income and capital-return component on top of pipeline optionality.
The bear case: what would have to be true for $215.00
The most pessimistic published target is $215.00, -45.2% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Amgen is worth if the risks below bite instead of the drivers above.
Amgen faces patent cliffs as older blockbusters lose exclusivity, exposing them to biosimilar competition and pricing pressure. Drug development is high-risk: pipeline candidates, including its obesity programs, can fail in late-stage trials or face regulatory setbacks. US drug-pricing policy, including Medicare negotiation under the Inflation Reduction Act, pressures margins on key products. The Horizon acquisition added debt. Litigation, manufacturing, and safety risks are inherent to the industry. Verify the latest pipeline and revenue trends before drawing conclusions.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding AMGN already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on AMGN
29 analysts cover AMGN, with an average target of $357.03 (-9.0% against $392.26) and a split of 14 buy, 17 hold, 3 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the AMGN forecast and price target page.
How is AMGN valued? (as of early 2026)
Snapshot for AMGN as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$33-35 billion (approximate, verify)
- Operating margin: ~30%+ (approximate, verify)
- P/E (TTM): ~20-25x (GAAP varies; approximate, verify)
- Dividend yield: ~3% (approximate, verify)
- Market cap: ~$150 billion-plus (approximate, verify)
- Net debt: Elevated after the Horizon acquisition (verify)
- Index membership: Dow Jones Industrial Average, S&P 500, Nasdaq-100
Amgen trades at a moderate multiple typical of a mature large-cap biopharma, reflecting steady cash flow and a meaningful dividend balanced against patent-cliff and drug-pricing risk. The valuation embeds expectations for the rare-disease and obesity pipelines to offset declines in older franchises. All figures are approximate and move with the share price and reported results; verify current numbers before relying on them.
How do you decide if AMGN is a buy?
Rather than asking whether AMGN is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold AMGN indirectly through an index or sector ETF before adding more.
What would change your mind on AMGN
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Rare disease and Horizon assets stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: amgen faces patent cliffs as older blockbusters lose exclusivity, exposing them to biosimilar competition and pricing pressure fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the AMGN stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about AMGN against your real portfolio and see your actual exposure before deciding.
Investing in Amgen with AI
Connect the broker you already use and ask Walnut's AI how AMGN fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is AMGN a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Rare disease and Horizon assets, with revenue (ttm) at ~$33-35 billion (approximate, verify). The bear case rests on amgen faces patent cliffs as older blockbusters lose exclusivity, exposing them to biosimilar competition and pricing pressure. Analysts covering it are spread from $215.00 to $427.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell AMGN?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Amgen faces patent cliffs as older blockbusters lose exclusivity, exposing them to biosimilar competition and pricing pressure. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $215.00, -45.2% from the $392.26 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for AMGN?
+
Rare disease and Horizon assets. The Horizon Therapeutics acquisition added higher-growth rare-disease drugs such as Tepezza and Krystexxa, diversifying Amgen away from older, slower-growing franchises and giving it newer products with patent runway and pricing power in specialty markets. The most optimistic analyst target on AMGN is $427.00, +8.9% from the $392.26 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for AMGN?
+
Amgen faces patent cliffs as older blockbusters lose exclusivity, exposing them to biosimilar competition and pricing pressure. Drug development is high-risk: pipeline candidates, including its obesity programs, can fail in late-stage trials or face regulatory setbacks. US drug-pricing policy, including Medicare negotiation under the Inflation Reduction Act, pressures margins on key products. The Horizon acquisition added debt. Litigation, manufacturing, and safety risks are inherent to the industry. Verify the latest pipeline and revenue trends before drawing conclusions. The most pessimistic published target is $215.00, -45.2% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does Amgen do?
+
One of the world's largest biotech companies, with a broad biologics portfolio plus growing rare-disease, biosimilar, and obesity pipelines.
What would have to change for AMGN to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Rare disease and Horizon assets) stalling in the reported numbers rather than in the narrative, the risk above (amgen faces patent cliffs as older blockbusters lose exclusivity, exposing them to biosimilar competition and pricing pressure) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What is Amgen's (AMGN) ticker symbol?
+
AMGN, listed on Nasdaq. Officially Amgen Inc. Founded in 1980 and headquartered in Thousand Oaks, California. It is a member of the Dow Jones Industrial Average, the S&P 500, and the Nasdaq-100, and trades during US market hours at every major US brokerage.
What does Amgen (AMGN) do?
+
Amgen is a large biotechnology company that develops, manufactures, and sells biologic medicines for serious illnesses across inflammation, oncology, cardiovascular disease, bone health, and rare diseases. Products have included Enbrel, Prolia, Xgeva, Repatha, Otezla, and rare-disease drugs from the Horizon acquisition such as Tepezza. It also develops biosimilars and a pipeline that includes obesity candidates.
Who are Amgen's (AMGN) main competitors?
+
Across therapeutic areas, Pfizer, Merck, AbbVie, Bristol Myers Squibb, Johnson and Johnson, Novartis, and Roche. In obesity, its candidates would compete with Eli Lilly and Novo Nordisk. In biosimilars, with Sandoz, Samsung Bioepis, Teva, and others.
Walnut is informational, not investment advice, and gives no verdict on AMGN. Analyst targets referenced here come from a July 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.
Guides that feature AMGN
AMGN is one of the names covered in these guides. Each one puts the stock next to its peers so you can see where it fits rather than judging it alone.